These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30142779)

  • 1. Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis.
    Gao C; Wang J; Li Y; Zhao H; Li R; Hou L; Zhang Y; Tian S; Liang H; Wang C; Chen X; Wang J
    Medicine (Baltimore); 2018 Aug; 97(34):e11860. PubMed ID: 30142779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
    Liu B; Guo Y; Deng L; Qiao Y; Jian J
    Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypomethylating agents for elderly patients with acute myeloid leukemia: a PRISMA systematic review and meta-analysis.
    Zhang RJ; Zhai JH; Zhang ZJ; Yang LH; Wang MF; Dong CX
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2577-2590. PubMed ID: 33829444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis.
    Ma J; Ge Z
    Front Pharmacol; 2021; 12():701690. PubMed ID: 34483903
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
    Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
    J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.
    Du Y; Li C; Zhao Z; Liu Y; Zhang C; Yan J
    BMC Cancer; 2023 Aug; 23(1):764. PubMed ID: 37592239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
    Feld J; Tremblay D; Navada SC; Silverman LR
    Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and meta
    Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
    Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
    Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
    Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
    Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
    Pan T; Qi J; You T; Yang L; Wu D; Han Y; Zhu L
    Leuk Res; 2018 Aug; 71():13-24. PubMed ID: 29936305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis.
    Zheng X; Lv L; Li X; Jiang E
    Glob Med Genet; 2022 Jun; 9(2):141-151. PubMed ID: 35707788
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
    Sekeres MA; Taylor J
    JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
    Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
    Savona MR; Kolibaba K; Conkling P; Kingsley EC; Becerra C; Morris JC; Rifkin RM; Laille E; Kellerman A; Ukrainskyj SM; Dong Q; Skikne BS
    Am J Hematol; 2018 Oct; 93(10):1199-1206. PubMed ID: 30016552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Daver N; Boddu P; Garcia-Manero G; Yadav SS; Sharma P; Allison J; Kantarjian H
    Leukemia; 2018 May; 32(5):1094-1105. PubMed ID: 29487386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.